Equity Overview
Price & Market Data
Price: $3.21
Daily Change: +$0.06 / 1.87%
Range: $2.92 - $3.27
Market Cap: $955,152,000
Volume: 7,090,659
Performance Metrics
1 Week: 31.15%
1 Month: 56.10%
3 Months: 26.98%
6 Months: 5.96%
1 Year: -6.71%
YTD: 9.22%
Company Details
Employees: 596
Sector: Health technology
Industry: Biotechnology
Country: Canada
Details
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.